Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290635 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6062459 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL20913074 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL31460273 | 0.85 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL205216 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL14992459 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL3898493 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2323942 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1841015 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1245110 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | ATHENEX, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20200071305-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2020-03-05 | — | — | US | disclosed |
| US-10450303-B2 | Biaryl piperidine amide compounds and methods of use thereof | ATHENEX, INC. (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | SMN1; SMN2 1593/4885NPC1 4748/4885RAB9A 3951/4885 |
| US-10450303-B2 | Biaryl piperidine amide compounds and methods of use thereof | AADAC, PAICS, UGT2B7 | SMN1; SMN2 3010/4885NPC1 771/4885RAB9A 775/4885 |
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, PAICS, UGT2B7 | SMN1; SMN2 3010/4885NPC1 771/4885RAB9A 775/4885 |
| US-20200071305-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, PAICS, UGT2B7 | SMN1; SMN2 3010/4885NPC1 771/4885RAB9A 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.